Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Apr;108(4):1117–1124. doi: 10.1111/j.1476-5381.1993.tb13514.x

Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.

J Semba 1, G Curzon 1, P N Patsalos 1
PMCID: PMC1908144  PMID: 8485621

Abstract

1. The kinetics and metabolism of milacemide have been studied in an animal model which allows the simultaneous investigation of the temporal inter-relationships of drugs and metabolites in blood (pharmacokinetics) and cerebrospinal fluid (CSF, neuropharmacokinetics) in individual freely moving rats. 2. Milacemide dose-dependently increased CSF glycine and glycinamide (intermediary metabolite) concentrations. This confirms that milacemide is a CNS glycine prodrug. 3. Pretreatment with L-deprenyl (2 mg kg-1), a specific inhibitor of monoamine oxidase type B (MAO-B), almost completely prevented the formation of glycinamide and increased milacemide accumulation in CSF. Tmax and t1/2 were significantly increased and Cmax and AUC values were decreased for glycinamide compared to controls. Pretreatment with clorgyline (5 mg kg-1), a specific inhibitor of MAO-type A, only moderately decreased glycinamide Cmax and AUC values. 4. After milacemide administration (100, 200 and 400 mg kg-1, i.p.) serum and CSF milacemide concentrations rose linearly and dose-dependently. Serum glycinamide concentrations exhibited small dose-dependent rises but these were not linearly related. In contrast, CSF glycinamide concentrations rose linearly and dose-dependently with Cmax values 2.5, 3.2 and 4.1 times greater than the corresponding values for serum glycinamide after giving 100, 200 and 400 mg kg-1 respectively of milacemide. 5. Serum glycine concentrations were unaffected but CSF concentrations increased dose-dependently and these were significant at the higher milacemide doses (200 and 400 mg kg-1). Animals given 400 mg kg-1 milacemide had glycine values which were still significantly elevated 7 h later.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1117

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aprison M. H., Werman R. The distribution of glycine in cat spinal cord and roots. Life Sci. 1965 Nov;4(21):2075–2083. doi: 10.1016/0024-3205(65)90325-5. [DOI] [PubMed] [Google Scholar]
  2. Bormann J., Hamill O. P., Sakmann B. Mechanism of anion permeation through channels gated by glycine and gamma-aminobutyric acid in mouse cultured spinal neurones. J Physiol. 1987 Apr;385:243–286. doi: 10.1113/jphysiol.1987.sp016493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brody T., Shin Y. S., Stokstad E. L. Rat brain folate identification. J Neurochem. 1976 Aug;27(2):409–413. doi: 10.1111/j.1471-4159.1976.tb12262.x. [DOI] [PubMed] [Google Scholar]
  4. Brown P., Thompson P. D., Rothwell J. C., Day B. L., Marsden C. D. A therapeutic trial of milacemide in myoclonus and the stiff-person syndrome. Mov Disord. 1991;6(1):73–75. doi: 10.1002/mds.870060114. [DOI] [PubMed] [Google Scholar]
  5. Christophe J., Kutzner R., Nguyen-Bui N. D., Damien C., Chatelain P., Gillet L. Conversion of orally administered 2-n.pentylaminoacetamide into glycinamide and glycine in the rat brain. Life Sci. 1983 Aug 8;33(6):533–541. doi: 10.1016/0024-3205(83)90127-3. [DOI] [PubMed] [Google Scholar]
  6. Danhof M., Levy G. Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J Pharmacol Exp Ther. 1984 Apr;229(1):44–50. [PubMed] [Google Scholar]
  7. Deutsch S. I., Mastropaolo J., Schwartz B. L., Rosse R. B., Morihisa J. M. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol. 1989 Feb;12(1):1–13. [PubMed] [Google Scholar]
  8. Dingemanse J., van Bree J. B., Danhof M. Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. J Pharmacol Exp Ther. 1989 May;249(2):601–608. [PubMed] [Google Scholar]
  9. Giuffra M. E., Mouradian M. M., Chase T. N. Glutamatergic therapy of Huntington's chorea. Clin Neuropharmacol. 1992 Apr;15(2):148–151. doi: 10.1097/00002826-199204000-00009. [DOI] [PubMed] [Google Scholar]
  10. Greenamyre J. T., Penney J. B., Young A. B., D'Amato C. J., Hicks S. P., Shoulson I. Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases. Science. 1985 Mar 22;227(4693):1496–1499. doi: 10.1126/science.2858129. [DOI] [PubMed] [Google Scholar]
  11. Handelmann G. E., Nevins M. E., Mueller L. L., Arnolde S. M., Cordi A. A. Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents. Pharmacol Biochem Behav. 1989 Dec;34(4):823–828. doi: 10.1016/0091-3057(89)90281-5. [DOI] [PubMed] [Google Scholar]
  12. Houtkooper M. A., van Oorschot C. A., Rentmeester T. W., Höppener P. J., Onkelinx C. Double-blind study of milacemide in hospitalized therapy-resistant patients with epilepsy. Epilepsia. 1986 May-Jun;27(3):255–262. doi: 10.1111/j.1528-1157.1986.tb03537.x. [DOI] [PubMed] [Google Scholar]
  13. Hutson P. H., Sarna G. S., Kantamaneni B. D., Curzon G. Monitoring the effect of a tryptophan load on brain indole metabolism in freely moving rats by simultaneous cerebrospinal fluid sampling and brain dialysis. J Neurochem. 1985 Apr;44(4):1266–1273. doi: 10.1111/j.1471-4159.1985.tb08753.x. [DOI] [PubMed] [Google Scholar]
  14. Janssens de Varebeke P., Cavalier R., David-Remacle M., Youdim M. B. Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B. J Neurochem. 1988 Apr;50(4):1011–1016. doi: 10.1111/j.1471-4159.1988.tb10566.x. [DOI] [PubMed] [Google Scholar]
  15. Janssens de Varebeke P., Pauwels G., Buyse C., David-Remacle M., De Mey J., Roba J., Youdim M. B. The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B. J Neurochem. 1989 Oct;53(4):1109–1116. doi: 10.1111/j.1471-4159.1989.tb07403.x. [DOI] [PubMed] [Google Scholar]
  16. Johnson J. W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 1987 Feb 5;325(6104):529–531. doi: 10.1038/325529a0. [DOI] [PubMed] [Google Scholar]
  17. Johnston J. P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968 Jul;17(7):1285–1297. doi: 10.1016/0006-2952(68)90066-x. [DOI] [PubMed] [Google Scholar]
  18. Kalir A., Sabbagh A., Youdim M. B. Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol. 1981 May;73(1):55–64. doi: 10.1111/j.1476-5381.1981.tb16771.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Klockowski P. M., Levy G. Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats. J Pharmacol Exp Ther. 1988 Mar;244(3):912–918. [PubMed] [Google Scholar]
  20. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972;5:393–408. [PubMed] [Google Scholar]
  21. Liu Z., Seiler N., Marescaux C., Depaulis A., Vergnes M. Potentiation of gamma-vinyl GABA (vigabatrin) effects by glycine. Eur J Pharmacol. 1990 Jun 21;182(1):109–115. doi: 10.1016/0014-2999(90)90498-u. [DOI] [PubMed] [Google Scholar]
  22. Minn A., Ghersi-Egea J. F., Perrin R., Leininger B., Siest G. Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res Brain Res Rev. 1991 Jan-Apr;16(1):65–82. doi: 10.1016/0165-0173(91)90020-9. [DOI] [PubMed] [Google Scholar]
  23. Oldendorf W. H. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol. 1971 Dec;221(6):1629–1639. doi: 10.1152/ajplegacy.1971.221.6.1629. [DOI] [PubMed] [Google Scholar]
  24. Paterson A M. Pectineus Muscle and its Nerve-Supply. J Anat Physiol. 1891 Oct;26(Pt 1):43–47. [PMC free article] [PubMed] [Google Scholar]
  25. Patsalos P. N., Alavijeh M. S., Semba J., Lolin Y. I. A freely moving and behaving rat model for the chronic and simultaneous study of drug pharmacokinetics (blood) and neuropharmacokinetics (cerebrospinal fluid): hematological and biochemical characterization and kinetic evaluation using carbamazepine. J Pharmacol Toxicol Methods. 1992 Aug;28(1):21–28. doi: 10.1016/1056-8719(92)90061-5. [DOI] [PubMed] [Google Scholar]
  26. Richter J. J., Wainer A. Evidence for separate systems for the transport of neutral and basic amino acids across the blood-brain barrier. J Neurochem. 1971 Apr;18(4):613–620. doi: 10.1111/j.1471-4159.1971.tb11991.x. [DOI] [PubMed] [Google Scholar]
  27. Rosse R. B., Schwartz B. L., Davis R. E., Deutsch S. I. An NMDA intervention strategy in schizophrenia with "low-dose" milacemide. Clin Neuropharmacol. 1991 Jun;14(3):268–272. doi: 10.1097/00002826-199106000-00012. [DOI] [PubMed] [Google Scholar]
  28. Saletu B., Grünberger J., Linzmayer L. Acute and subacute CNS effects of milacemide in elderly people: double-blind, placebo-controlled quantitative EEG and psychometric investigations. Arch Gerontol Geriatr. 1986 Oct;5(3):165–181. doi: 10.1016/0167-4943(86)90019-1. [DOI] [PubMed] [Google Scholar]
  29. Schwartz B. L., Hashtroudi S., Herting R. L., Deutsch S. I. The effects of milacemide on item and source memory. Clin Neuropharmacol. 1992 Apr;15(2):114–119. doi: 10.1097/00002826-199204000-00005. [DOI] [PubMed] [Google Scholar]
  30. Semba J., Doheny M., Patsalos P. N., Sarna G., Curzon G. Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex. Br J Pharmacol. 1992 Jan;105(1):59–62. doi: 10.1111/j.1476-5381.1992.tb14210.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Semba J., Ratnaraj N., Patsalos P. N. Simple and rapid micro-analytical procedures for the estimation of milacemide and its metabolite glycinamide in rat plasma and cerebrospinal fluid by high-performance liquid chromatography. J Chromatogr. 1991 Apr 19;565(1-2):357–362. doi: 10.1016/0378-4347(91)80396-t. [DOI] [PubMed] [Google Scholar]
  32. Sokomba E. N., Patsalos P. N., Lolin Y. I., Curzon G. Concurrent monitoring of central carbamazepine and transmitter amine metabolism and motor activity in individual unrestrained rats using repetitive withdrawal of cerebrospinal fluid. Neuropharmacology. 1988 Apr;27(4):409–415. doi: 10.1016/0028-3908(88)90150-5. [DOI] [PubMed] [Google Scholar]
  33. Toth E., Lajtha A. Elevation of cerebral levels of nonessential amino acids in vivo by administration of large doses. Neurochem Res. 1981 Dec;6(12):1309–1317. doi: 10.1007/BF00964352. [DOI] [PubMed] [Google Scholar]
  34. Toth E., Lajtha A., Sarhan S., Seiler N. Anticonvulsant effects of some inhibitory neurotransmitter amino acids. Neurochem Res. 1983 Mar;8(3):291–302. doi: 10.1007/BF00965719. [DOI] [PubMed] [Google Scholar]
  35. Truong D. D., Fahn S. Therapeutic trial with glycine in myoclonus. Mov Disord. 1988;3(3):222–232. doi: 10.1002/mds.870030306. [DOI] [PubMed] [Google Scholar]
  36. Turnell D. C., Cooper J. D. Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography. Clin Chem. 1982 Mar;28(3):527–531. [PubMed] [Google Scholar]
  37. Waziri R. Glycine therapy of schizophrenia. Biol Psychiatry. 1988 Jan 15;23(2):210–211. doi: 10.1016/0006-3223(88)90093-5. [DOI] [PubMed] [Google Scholar]
  38. de Varebeke P. J., Niebes P., Pauwels G., Roba J., Korf J. Effect of milacemide, a glycinamide derivative, on the rat brain gamma-aminobutyric acid system. Biochem Pharmacol. 1983 Sep 15;32(18):2751–2755. doi: 10.1016/0006-2952(83)90087-4. [DOI] [PubMed] [Google Scholar]
  39. van Dorsser W., Barris D., Cordi A., Roba J. Anticonvulsant activity of milacemide. Arch Int Pharmacodyn Ther. 1983 Dec;266(2):239–249. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES